UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2003
Callisto Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 333-63474 13-3894575
(State or other jurisdiction (Commission (IRS Employer
of incorporation or organization) File Number) Identification No.)
420 Lexington Avenue, Suite 601
New York, New York 10170
(Address of principal executive offices)
Registrant's telephone number, including area code: (212) 672-9190
(Former name or former address, if changed since last report)
Item 4 Changes in Registrant's Certifying Accountant
(a) Previous independent accountants
(i) On August 5, 2003, Baum & Company, PA resigned as the independent
accountants of Callisto Pharmaceuticals, Inc.
(ii) The reports of Baum & Company, PA on the financial statements for
the past two fiscal years contained no adverse opinion or disclaimer of opinion
and were not qualified or modified as to uncertainty, audit scope or accounting
principles.
(iii) In connection with its audits for the two most recent fiscal
years and the subsequent interim period through the date of this report, there
have been no disagreements with Baum & Company, PA on any matter of accounting
principles or practices, financial statement disclosure, or auditing scope or
procedure, which disagreements if not resolved to the satisfaction of Baum &
Company, PA would have caused them to make reference thereto in their report on
the financial statements for such years.
(iv) During the two most recent fiscal years and the subsequent interim
period through the date of this report, there have been no reportable events (as
defined in Regulation S-K Item 304(a)(1)(v)).
(v) The Registrant has requested that Baum & Company, PA furnish it
with a letter addressed to the SEC stating whether or not it agrees with the
above statements. A copy of such letter, dated August 6, 2003 is filed as
Exhibit 16 to this Form 8-K.
(b) New independent accountants
(i) The Registrant engaged BDO Seidman LLP ("BDO") as its new
independent accountants as of August 5, 2003. During the two most recent fiscal
years and the subsequent interim period through the date of this report, the
Registrant has not consulted with BDO regarding either (i) the application of
accounting principles to a specified transaction, either completed or proposed;
or the type of audit opinion that might be rendered on the Registrant's
financial statements, and neither a written report was provided to the
Registrant nor was oral advice provided that BDO concluded was an important
factor considered by the Registrant in reaching a decision as to the accounting,
auditing or financial reporting issue; or (ii) any matter that was either the
subject of a disagreement, as that term is defined in Item 304(a)(1)(iv) of
Regulation S-K and the related instructions to Item 304 of Regulation S-K, or a
reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation
S-K.
Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
16 Letter from Baum & Company, PA Re: Change in Certifying
Accountant
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereto duly authorized.
Dated: August 6, 2003
CALLISTO PHARMACEUTICALS, INC.
By: /s/ Gary S. Jacob
-------------------------------
Gary S. Jacob, Ph.D.
Chief Executive Officer
3